A contração muscular esquelética é regulada pelo complexo troponina/tropomiosina de maneira dependente de Ca2+. O complexo troponina consiste de três subunidades: a troponina C (TnC), a troponina I (TnI) e a troponina T (TnT). A troponina C é a subunidade que liga Ca2+, a TnI é a subunidade inibitória e a TnT liga-se fortemente à tropomiosina. A TnI e a TnT são altamente insolúveis a baixas forças iônicas, a não ser que estejam complexadas com a TnC. O complexo troponina pode ser reconstituído \"in vitro\" a partir das subunidades isoladas simplesmente misturando-se as subunidades em razões equimolares em uréia, que depois é removida através de diálise. Na primeira parte deste trabalho um vetor para a co-expressão da TnC, TnI e TnT em E.coli foi construído. Utilizando este vetor nós produzimos um complexo troponina funcional montado no citoplasma de E.coli. A presença da TnT é requerida para regulação dependente de Ca2+ da contração muscular esquelética. O papel da TnT em conferir sensibilidade ao Ca2+ à atividade ATPásica da acto-miosina foi analisado. Mutantes de deleção da TnT foram construídos através de mutação sítio-dirigida e expressos em E.coli. Complexos troponina contendo os mutantes de TnT e/ou mutantes de TnI foram reconstituídos e analisados em ensaios de ligação ao filamento fino e ensaios de atividade ATPásica. Baseado nestes resultados a TnT foi subdividida em três domínios: o domínio ativatório (aminoácidos 157-216), o domínio inibitório (aminoácidos 157-216) e o domínio de ancoragem do dímero TnC/TnI (aminoácidos 216-263). Nós demonstramos que o dímero TnC/TnI está ancorado ao filamento fino através da interação entre a região amino-terminal da TnI e da região carbóxi-terminal da TnT (aminoácidos 216-263). Um modelo para o papel da TnT na regulação da contração muscular dependente de Ca2+ é proposto. / The contraction of skeletal muscle is regulated by troponin and tropomyosin in a Ca2+ dependent manner. The troponin complex consists of three subunits: troponin C (TnC), troponin I (TnI) and troponin T (TnT). Troponin C is the Ca2+ binding subunit, TnI is the inhibitory subunit and TnT binds tightly to tropomyosin. TnI and TnT are highly insoluble proteins at low ionic strengths, unless they are complexed with TnC. The troponin complex can be reconstituted \"in vitro\" from the isolated subunits simply by mixing the subunits at equimolar ratios in urea, which is then removed by dialysis. In the first part of this work a vector for the co-expression of TnC, TnI and TnT in E.coli was constructed. Using this vector we were able to produce a functional troponin complex assembled \"in vivo\" in the E.coli cytoplasm The presence of TnT is required for the Ca2+ dependente regulation of the skeletal muscle contraction. The role of TnT in conferring full Ca2+ sensitivity to the ATPase activity of acto-myosin was analyzed. Deletion mutants of TnT were constructed by site-directed mutagenesis and expressed in E.coli. Troponin complexes containing the TnT deletion mutants and/or TnI deletion mutants, were reconstituted and analyzed in thin filament binding assays and in ATPase activity assays. Based on these studies, TnT was subdivided into three domains: the activation domain (comprised of aminoacids 1-157), the inhibitory domain (comprised of amino acids 157-216) and the TnC/TnI dimer anchoring domain (aminoacids 216-263). We demonstrated that the TnC/TnI is anchored to the thin filament through interaction between the amino-terminal domain of TnI and the region comprised of aminoacids 216-263 of TnT. A model for the role of TnT in the Ca2+ dependent regulation of muscle contraction is proposed.

Abstract The first aim of this study was to investigate the relationship between Doppler ultrasonographic parameters and biochemical markers of human fetal cardiac dysfunction and myocardial cell damage in pregnancies complicated by placental insufficiency and/or fetal growth restriction. Our second aim was to examine fetal central and peripheral hemodynamic characteristics associated with retrograde aortic isthmus net blood flow. Fetuses with significant myocardial cell damage (cTnT > 0.10 ng/ml) had increased pulsatility in the blood velocity waveforms of ductus venosus, left hepatic vein and inferior vena cava, and had more often atrial pulsations in the umbilical vein. Their umbilical artery NT-proANP concentrations were higher than in fetuses without myocardial cell damage. The proportion of left ventricular cardiac output of the combined cardiac output was greater and the corresponding proportion of the right ventricle was less than in fetuses with only increased NT-proANP levels ( > 1145 pmol/l). Tricuspid regurgitation was present more often and the right ventricular fractional shortening was less in fetuses with myocardial cell damage than in fetuses with normal umbilical artery cTnT levels. In fetuses with placental insufficiency and/or growth restriction (n = 48), umbilical artery NT-proANP concentrations showed a significant positive correlation with ductus venosus, left hepatic vein and inferior vena cava pulsatility index values for veins. Fetuses with placental insufficiency and antegrade aortic isthmus net blood flow demonstrated a shift in their right ventricular cardiac output from the pulmonary to the systemic circulation, and foramen ovale volume blood flow made up the majority of the left ventricular cardiac output. Fetuses with retrograde aortic isthmus net blood flow failed to demonstrate these changes, and they had signs of increased left atrial pressure. In addition, right ventricular fractional shortening was decreased and the pulsatility in the ductus venosus blood velocity waveforms was increased. In conclusion, human fetal myocardial cell damage was associated with a rise in systemic venous pressure, a change in the distribution of cardiac output towards the left ventricle and a rise in right ventricular afterload. Fetuses with retrograde aortic isthmus net blood flow failed to rearrange the distribution of the cardiac output and they had signs of increased left atrial pressure. In addition, right ventricular afterload and pulsatility in the ductus venosus blood velocity waveforms were increased.

Numerous troponin T (TnT) isoforms are generated by alternative RNA splicing primarily in its NH2-terminal hypervariable region, but the functions of these isoforms are not completely understood. In this dissertation work, calcium and terbium binding behavior of several forms of TnT were investigated by spectroscopic and radioactive techniques. Chicken breast muscle TnT binds calcium and terbium through its NH2-terminal Tx motif (HEEAH)n with high affinity (10-6 mM) and fast on-rate (106 - 107 M-1 s-1). Chicken leg muscle TnT and a human cardiac TnT NH2-terminal fragment, which both lack the Tx motif on their NH2-terminal regions, do not have affinities for calcium in the physiological range. Computational predictions on TnT N47 suggest that the TnT NH2-terminal region might fold into an elongated structure with at least one high affinity metal ion binding pocket comprised primarily of the Tx motif sequence and several lower affinity binding sites. In addition, calcium binding to TnT N47 might alter its conformation and flexibility. Luminescence resonance energy transfer measurements and other experimental observations are consistent with the computational predictions suggesting the computational simulated atomic model is reasonable. TnT mutations are responsible for 15% of familiar hypertrophic cardiomyopathy (FHC) cases with a phenotype of relatively mild hypertrophy, but a high incidence of sudden death. Detection of those genetic mutations would facilitate the clinical diagnosis and initiation of treatment at an early stage. This dissertation also investigated a novel hybridization proximity assay (HYPA) combining molecular beacon and luminescence resonance energy transfer (LRET) technologies. Experimental results suggest that a shared stem probe design produces a more consistent response upon hybridization, whereas the internally labeled probe was less consistent, but can yield the highest responses. Using the optimally designed molecular probes, the HYPA provides a detection of alterations in nucleic acid structure of as little as a single nucleotide. This novel HYPA is expected to expand its applications in the analysis and screening of genetic diseases.

Submitted by Fabio Sobreira Campos da Costa (fabio.sobreira@ufpe.br) on 2016-04-19T15:38:52Z No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Tese Sérgio Rocha para Defesa OK.pdf: 3444360 bytes, checksum: da9ca3f2c9d898e60430ef1b21bd681a (MD5) / Made available in DSpace on 2016-04-19T15:38:52Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Tese Sérgio Rocha para Defesa OK.pdf: 3444360 bytes, checksum: da9ca3f2c9d898e60430ef1b21bd681a (MD5) Previous issue date: 2015-02-25 / O infarto agudo do miocárdio (IAM) representa hoje um dos maiores problemas de saúde mundial prevalecendo sobre doenças como câncer, AIDS e doenças respiratórias. Em virtude da relevância, métodos cada vez mais eficientes para auxilio no diagnóstico do IAM vem sendo desenvolvidos. Um destes métodos, os aptassensores, chegam como ferramenta analítica alternativa para detecção de marcadores de necrose miocárdica. Neste trabalho um aptassensor simples e livre de marcação foi desenvolvido para detecção de troponina T cardíaca (cTnT), para isto, nanopartículas de prata foram sintetizadas eletroquimicamente sobre eletrodos impressos de tinta de carbono. Em seguida, 5 μL de cisteína foi adicionada à superfície sensora com intuito de servir de braço químico e possibilitar a imobilização do aptâmero. O aptâmero usado consiste em DNA fita simples modificado com grupos amino (NH2-ssDNA) e específico para o analito em questão. As condições ideais para imobilização do aptâmero e reconhecimento da molécula alvo, assim como a caracterização eletroquímica do aptassensor, foram investigados através das técnicas de voltametria cíclica (CV) e voltametria de pulso diferencial (DPV). A especificidade do aptassensor foi investigada utilizando para isso moléculas alvo específicas e inespecíficas. O reconhecimento do alvo apresentou alta sensibilidade com limite de detecção em 0,1 ng mL−1 de cTnT e uma boa reprodutibilidade (CV = 4%). O sensor também foi testado com amostras de soro humano, apresentando ótima concordância (95% de nível de confiança) com o padrão ouro, o método ECLIA. Neste trabalho pôde-se constatar que as nanopartículas de prata incorporadas a superfície eletródica melhoraram a reprodutibilidade, a condutividade e, consequentemente a resposta sensora, enquanto os aptâmeros asseguraram a sensibilidade e especificidade do aptasensor, apresentando, este modelo, grande potencial para uso no monitoramento dos níveis séricos de troponina cardíaca. / Acute myocardial infarction (AMI) it is one of the most serious diseases in the world responsible for approximately 17 million of deaths in 2012. Therefore, early diagnosis and prompt medical response are of paramount importance for patient survival. Aptasensors can be an alternative, which in combination with electrochemical techniques can provide the simplicity and speed required. A simple and sensitive label-free aptasensor for cardiac troponin T (cTnT) detection was successfully developed. For this purpose, it was chosen a DNA aptamers modified with amino group (NH2-ssDNA) specific to bind cTnT with a high specificity and stability. Herein, silver nanoparticles electrochemically synthesized and cysteine were used to modify the electrode, providing binding sites for aptamer immobilization. The optimum conditions for immobilization of the aptamer and target recognition were investigated by cyclic voltammetry (CV) and differential pulse voltammetry (DPV) technique. The aptasensor achieved a low limit of detection (0.3 ng mL−1) and a linear range between 0.1 and 10 ng mL−1 cTnT, significant for acute myocardial infarction diagnosis. Good reproducibility was obtained by the proposed aptasensor supported by a coefficient of variation of 4%. The silver nanoparticles incorporated to the electrode surface improved the reproducibility, while the aptamer secured the sensitivity of the biosensor. The sensor was also tested for human serum samples presenting a good agreement with the ECLIA methods at 95% confident level. This point-of-care approach presents a great potential for use in several situations releasing the aptasensor for use in the cardiac troponin detection.

Die ersten identifizierten Krankheitsgene der dilatativen Kardiomyopathie (DCM) kodierten alle für Proteine des Zytoskeletts. Deshalb wurde DCM als Erkrankung des Zytoskeletts bezeichnet. Bei der hypertrophen Kardiomyopathie (HCM) wurden bisher mehr als 250 Mutationen in neun Sarkomerprotein-Genen beschrieben. Deshalb wurde HCM als Erkrankung des Sarkomers bezeichnet. In den letzten Jahren wurde dieses Konzept durch Entdeckung von Mutationen in Sarkomerprotein-Genen bei DCM jedoch in Frage gestellt. Vor diesem Hintergrund haben wir die Sarkomerprotein-Gene beta-MHC und Troponin T bei 46 nicht verwandten DCM-Patienten untersucht. Das systematische Mutationsscreening wurde mit Hilfe von SSCP-Analyse und DNA-Sequenzierung durchgeführt. Im beta-MHC-Gen konnten wir die zwei Missense-Mutationen Ala223Thr und Ser642Leu bei zwei jungen Patienten identifizieren. Beide Mutationen wurden weder bei 136 HCM-Patienten noch bei 88 Kontrollen gefunden. Mit dem Editor for Structural Alignment of Proteins (STRAP) wurden die Mutationen auf die Proteinstruktur des Myosins projiziert. Hier ist erkennbar, dass Ala223Thr in der oberen 50 kDa Domäne und Ser642Leu in der Aktin-Myosin-Bindungsregion liegt. Der Austausch von Alanin zu Threonin könnte die Raumstruktur des Proteins verändern, Thermostabilität verringern und die Proteinfaltung und somit die Proteinmotilität beeinträchtigen. In der Aktin-Myosin-Bindungsregion liegt neben Ser642Leu die bereits bekannte DCM-assoziierte Mutation Ser532Pro. Durch eine Verminderung der Krafterzeugung könnten die beiden Mutationen zu DCM führen. Ferner wurden die zwei stummen Mutationen IVS11+23A>T und Asp376Asp und sechs Polymorphismen identifiziert. Im Troponin T-Gen wurden keine Mutationen, jedoch sechs Polymorphismen beobachtet. Es ergab sich kein Anhaltspunkt auf eine funktionelle Relevanz der stummen Mutationen oder Polymorphismen. Wir konnten also bestätigen, dass Mutationen in Sarkomerprotein-Genen sowohl zu HCM als auch zu DCM führen können. / All of the initially identified disease-causing genes in dilated cardiomyopathy (DCM) encoded proteins of the cytoskeleton. Therefore DCM has been termed a disease of the cytoskeleton. In hypertrophic cardiomyopathy (HCM) more than 250 mutations in nine sarcomeric protein genes have been identified so far. Therefore HCM has been termed a disease of the sarcomere. However, in the last few years this concept has been queried by findings of mutations in sarcomeric protein genes in DCM. According to this consideration we screened the sarcomeric protein genes beta-MHC and troponin T in 46 patients with DCM. Systematic mutation screening was done using SSCP analysis and DNA sequencing. In the beta-MHC gene we identified the two missense mutations Ala223Thr and Ser642Leu in two young patients. Both mutations were neither found in 136 HCM patients nor in 88 controls. Using the Editor for Structural Alignment of Proteins (STRAP) the mutations were projected onto the protein structure of myosin. Ala223Thr turned out to be localized in the upper 50 kDa domain and Ser642Leu in the actin-myosin-interface region. The exchange from alanine to threonine might alter the spatial structure of the protein, decrease its thermostability and affect the protein folding and thus the protein motility. Closely to Ser642Leu the DCM-associated mutation Ser532Pro is located in the actin-myosin-interface region. By a decrease in force production both mutations might cause DCM. Furthermore we identified the two silent mutations IVS11+23A>T and Asp376Asp and six polymorphisms. In the troponin T gene no mutations but six polymorphisms were detected. No evidence was found for functional relevance of the silent variants or polymorphisms. Thus, we could confirm that mutations in sarcomeric protein genes can lead to both HCM and DCM.

Objetivo: Avaliar a relação entre os parâmetros da cardiotocografia computadorizada (cCTG) e da dopplervelocimetria com a lesão miocárdica fetal e com a ocorrência de acidemia no nascimento, em gestações com insuficiência placentária. Métodos: Estudo prospectivo com 49 gestações complicadas pela insuficiência placentária (Doppler de artéria umbilical anormal - índice de pulsatilidade [IP] > p95) diagnosticada entre 26 e 34 semanas. Todas as pacientes foram avaliadas pelo Doppler de artéria umbilical, artéria cerebral média e ducto venoso e pela cCTG (Sonicaid FetalCare, versão 2.2, por 30 minutos). Foi analisada a última avaliação fetal até 48h antes do parto e anterior à corticoterapia. Foi analisado o sangue de cordão umbilical no parto, para detectar a acidemia no nascimento (pH < 7,20) e a lesão miocárdica fetal (Troponina T cardíaca [cTnT] >= 0,09 ng/mL). A cTnT foi obtida em 38 casos e o pH em 46 casos. Resultados: Quinze (39,5%) recém-nascidos apresentaram cTnT >= 0,09 ng/ml e 20 (43,5%) pH < 7,20. Os fetos que evoluíram com acidemia apresentaram menor número de movimentos por hora na cCTG (mediana 2 vs. 15, p=0,019). Houve correlação positiva entre o pH e o número de movimentos fetais por hora (rho=0,35; P=0,019) e com a frequência cardíaca fetal basal (rho 0,37, P=0,011), e correlação negativa entre o pH e o escore zeta do IP para veias (IPV) do ducto venoso (rho= -0,31, P=0,036). A regressão logística identificou o escore-zeta do IPV do ducto venoso (P=0,023) e a frequência cardíaca fetal basal (P=0,040) como variáveis independentes associadas com a acidemia no nascimento. A ocorrência de lesão miocárdica fetal, quando comparada ao grupo com cTnT normal, apresentou associação significativa com o escore zeta do IP da artéria umbilical (mediana 8,8 vs. 4,0; P=0,003), IPV do ducto venoso (mediana 2,6 vs. -1,4; P= 0,007), frequência cardíaca fetal basal (mediana 146 vs. 139 bpm; P=0,033), número de acelerações entre 10-15 bpm (mediana 0 vs. 1; P=0,013), duração dos episódios de baixa variação (mediana 21 vs. 10 min; P=0,038) e a variação de curto prazo (short-term variation-STV) (mediana 3,7 vs. 6,1 ms; P=0,003). Observou-se correlação positiva entre o valor da cTnT no cordão umbilical e a frequência cardíaca fetal basal (rho=0,33; P=0,042), e correlação negativa entre a cTnT e a STV (rho= -0,37; P=0,021). A regressão logística identificou a STV como fator preditor independente para o dano miocárdico fetal (P=0,01), sendo a STV <= 4,3 ms o melhor ponto de corte para predição do evento (sensibilidade de 66,7% e especificidade de 91,3%). Conclusão: Em gestações com insuficiência placentária detectada antes da 34ª semana gestacional, o IPV do ducto venoso e a frequência cardíaca fetal basal analisada pela cCTG são os preditores independentes associados com a acidemia no nascimento; e o valor da STV avaliada pela cCTG é a variável que melhor prediz a lesão miocárdica fetal. A cCTG é ferramenta importante no manejo de fetos com insuficiência placentária, principalmente quando associada a outros métodos propedêuticos como a dopplervelocimetria / Objective: To evaluate the reliability of fetal heart rate parameters analyzed by computerized cardiotocography (cCTG) and fetal Doppler to predict myocardial damage and acidemia at birth in pregnancies complicated by placental insufficiency. Methods: Forty nine patients with placental insufficiency (abnormal umbilical artery Doppler - pulsatility index [PI] > p95) diagnosed between 26-34 weeks of gestation were prospectively studied. All patients were submitted to Dopplervelocimetry of umbilical artery, middle cerebral artery and ductus venosus and to the cCTG (Sonicaid Fetal Care, version 2.2; 30 minutes of duration). We analyzed the last fetal assessment 48h before delivery and prior to steroid therapy.Umbilical cord blood samples were collected at birth to detect acidemia (pH < 7.20) and myocardial damage (cTnT >= 0.09 ng/ml). The results of cTnT were available in 38 cases and in 46 cases we had the pH values. Results: Fifteen (39.5%) newborns had cTnT >= 0.09 ng/ml and 20 (43.5%) had a pH < 7.20. Fetuses who developed acidemia had fewer fetal movements per hour in cCTG (median 2 vs. 15, P=0.019). There was a positive correlation between pH and the number of fetal movements per hour (rho 0.35, P=0.019) and basal fetal heart rate (rho 0.37, P=0.011), and a negative correlation between pH and the zscore of pulsatility index for veins (PIV) of ductus venosus (rho= -0.31, P=0.036). The logistic regression analysis identified the z-score of PIV of ductus venosus (P=0.023) and basal fetal heart rate (P=0.040) as independent variables associated with acidemia at birth. The occurrence of fetal myocardial injury was significantly associated with z-score of PI of umbilical artery (median 8.8 vs. 4.0, P=0.003), PIV of ductus venosus (median 2.6 vs. -1.4, P=0.007), basal fetal heart rate (median 146 vs. 139 bpm, P=0.033), number of accelerations between 10-15 bpm (median 0 vs. 1, P=0.013), duration of episodes of low variation (median 21 vs. 10 min, P=0.038) and short-term variation (STV) (median 3.7 vs. 6.1 ms, P=0.003). We observed a positive correlation between the value of cTnT in the umbilical cord and basal fetal heart rate (rho=0.33, P=0.042), and a negative correlation between cTnT and STV (rho=-0.37, P=0.021). Logistic regression identified the STV as an independent predictor for myocardial damage (P=0.01), and STV <= 4.3 ms was the best cutoff to predict the event (sensitivity 66.7% and specificity of 91.3%). Conclusion: In pregnancies with placental insufficiency detected before the 34th week of gestation, the PIV of ductus venosus and basal fetal heart rate analyzed by cCTG are independent variables associated with acidemia at birth; and the STV is the parameter that best predicts fetal myocardial injury. The cCTG is an important tool in the management of fetuses with placental insufficiency, especially when associated with other diagnostic methods such as Doppler

Objetivo: Avaliar a relação entre os parâmetros da cardiotocografia computadorizada (cCTG) e da dopplervelocimetria com a lesão miocárdica fetal e com a ocorrência de acidemia no nascimento, em gestações com insuficiência placentária. Métodos: Estudo prospectivo com 49 gestações complicadas pela insuficiência placentária (Doppler de artéria umbilical anormal - índice de pulsatilidade [IP] > p95) diagnosticada entre 26 e 34 semanas. Todas as pacientes foram avaliadas pelo Doppler de artéria umbilical, artéria cerebral média e ducto venoso e pela cCTG (Sonicaid FetalCare, versão 2.2, por 30 minutos). Foi analisada a última avaliação fetal até 48h antes do parto e anterior à corticoterapia. Foi analisado o sangue de cordão umbilical no parto, para detectar a acidemia no nascimento (pH < 7,20) e a lesão miocárdica fetal (Troponina T cardíaca [cTnT] >= 0,09 ng/mL). A cTnT foi obtida em 38 casos e o pH em 46 casos. Resultados: Quinze (39,5%) recém-nascidos apresentaram cTnT >= 0,09 ng/ml e 20 (43,5%) pH < 7,20. Os fetos que evoluíram com acidemia apresentaram menor número de movimentos por hora na cCTG (mediana 2 vs. 15, p=0,019). Houve correlação positiva entre o pH e o número de movimentos fetais por hora (rho=0,35; P=0,019) e com a frequência cardíaca fetal basal (rho 0,37, P=0,011), e correlação negativa entre o pH e o escore zeta do IP para veias (IPV) do ducto venoso (rho= -0,31, P=0,036). A regressão logística identificou o escore-zeta do IPV do ducto venoso (P=0,023) e a frequência cardíaca fetal basal (P=0,040) como variáveis independentes associadas com a acidemia no nascimento. A ocorrência de lesão miocárdica fetal, quando comparada ao grupo com cTnT normal, apresentou associação significativa com o escore zeta do IP da artéria umbilical (mediana 8,8 vs. 4,0; P=0,003), IPV do ducto venoso (mediana 2,6 vs. -1,4; P= 0,007), frequência cardíaca fetal basal (mediana 146 vs. 139 bpm; P=0,033), número de acelerações entre 10-15 bpm (mediana 0 vs. 1; P=0,013), duração dos episódios de baixa variação (mediana 21 vs. 10 min; P=0,038) e a variação de curto prazo (short-term variation-STV) (mediana 3,7 vs. 6,1 ms; P=0,003). Observou-se correlação positiva entre o valor da cTnT no cordão umbilical e a frequência cardíaca fetal basal (rho=0,33; P=0,042), e correlação negativa entre a cTnT e a STV (rho= -0,37; P=0,021). A regressão logística identificou a STV como fator preditor independente para o dano miocárdico fetal (P=0,01), sendo a STV <= 4,3 ms o melhor ponto de corte para predição do evento (sensibilidade de 66,7% e especificidade de 91,3%). Conclusão: Em gestações com insuficiência placentária detectada antes da 34ª semana gestacional, o IPV do ducto venoso e a frequência cardíaca fetal basal analisada pela cCTG são os preditores independentes associados com a acidemia no nascimento; e o valor da STV avaliada pela cCTG é a variável que melhor prediz a lesão miocárdica fetal. A cCTG é ferramenta importante no manejo de fetos com insuficiência placentária, principalmente quando associada a outros métodos propedêuticos como a dopplervelocimetria / Objective: To evaluate the reliability of fetal heart rate parameters analyzed by computerized cardiotocography (cCTG) and fetal Doppler to predict myocardial damage and acidemia at birth in pregnancies complicated by placental insufficiency. Methods: Forty nine patients with placental insufficiency (abnormal umbilical artery Doppler - pulsatility index [PI] > p95) diagnosed between 26-34 weeks of gestation were prospectively studied. All patients were submitted to Dopplervelocimetry of umbilical artery, middle cerebral artery and ductus venosus and to the cCTG (Sonicaid Fetal Care, version 2.2; 30 minutes of duration). We analyzed the last fetal assessment 48h before delivery and prior to steroid therapy.Umbilical cord blood samples were collected at birth to detect acidemia (pH < 7.20) and myocardial damage (cTnT >= 0.09 ng/ml). The results of cTnT were available in 38 cases and in 46 cases we had the pH values. Results: Fifteen (39.5%) newborns had cTnT >= 0.09 ng/ml and 20 (43.5%) had a pH < 7.20. Fetuses who developed acidemia had fewer fetal movements per hour in cCTG (median 2 vs. 15, P=0.019). There was a positive correlation between pH and the number of fetal movements per hour (rho 0.35, P=0.019) and basal fetal heart rate (rho 0.37, P=0.011), and a negative correlation between pH and the zscore of pulsatility index for veins (PIV) of ductus venosus (rho= -0.31, P=0.036). The logistic regression analysis identified the z-score of PIV of ductus venosus (P=0.023) and basal fetal heart rate (P=0.040) as independent variables associated with acidemia at birth. The occurrence of fetal myocardial injury was significantly associated with z-score of PI of umbilical artery (median 8.8 vs. 4.0, P=0.003), PIV of ductus venosus (median 2.6 vs. -1.4, P=0.007), basal fetal heart rate (median 146 vs. 139 bpm, P=0.033), number of accelerations between 10-15 bpm (median 0 vs. 1, P=0.013), duration of episodes of low variation (median 21 vs. 10 min, P=0.038) and short-term variation (STV) (median 3.7 vs. 6.1 ms, P=0.003). We observed a positive correlation between the value of cTnT in the umbilical cord and basal fetal heart rate (rho=0.33, P=0.042), and a negative correlation between cTnT and STV (rho=-0.37, P=0.021). Logistic regression identified the STV as an independent predictor for myocardial damage (P=0.01), and STV <= 4.3 ms was the best cutoff to predict the event (sensitivity 66.7% and specificity of 91.3%). Conclusion: In pregnancies with placental insufficiency detected before the 34th week of gestation, the PIV of ductus venosus and basal fetal heart rate analyzed by cCTG are independent variables associated with acidemia at birth; and the STV is the parameter that best predicts fetal myocardial injury. The cCTG is an important tool in the management of fetuses with placental insufficiency, especially when associated with other diagnostic methods such as Doppler

Background: Heart damage from cancer therapy is a significant problem for survivors. Some of the most effective treatments, such as anthracyclines, cause heart toxicity that can lead to significant morbidity and mortality. Cardiotoxicity also contributes to the loss of promising cancer drugs in early development and is notoriously difficult to predict. This translational project employs parallel pre-clinical and clinical studies to explore circulating biomarkers and cardiac magnetic resonance imaging (CMR) during development of anthracycline associated cardiotoxicity with the aim of finding biomarkers to aid clinical decision making and enable forward/back translation. Methods: Pre-clinical work: A rat model of chronic anthracycline-induced cardiomyopathy was developed involving 8 weekly intravenous boluses of doxorubicin followed by a 4 week ‘washout’ period. A time course assessment of cardiac function using multiple MRI parameters was performed alongside a panel of circulating biomarkers measured prior to dosing. Clinical work: In parallel following ethical approval, 30 cancer patients receiving standard anthracycline chemotherapy were recruited. Serial CMR scans were performed using standard and new exploratory techniques before, during and after treatment and blood was taken to evaluate a similar panel of cardiotoxicity biomarkers using multiplex ELISA at corresponding time points. Results: Pre-clinical results: Systolic and diastolic function declined progressively, culminating in left ventricular dysfunction (LVEF < 50%) by 12 weeks. Myocardial electron microscopy revealed myofibrillar and mitochondrial damage after one dose and gross histopathological damage after 5 doses. Myocardial contrast enhancement and troponin I increased significantly after eight doses and preceded LV dysfunction. Extensive fibrosis was seen 1 month after drug cessation. Clinical results: LVEF declined progressively in all patients and 7 patients (23%) had persistent LV dysfunction 12 months after therapy. Troponin I elevations were seen towards the end of therapy and peak troponin I corresponded with LVEF decline. None of the other circulating biomarkers correlated strongly with outcome. Lower baseline extracellular volume (ECV) was associated with greater LVEF decline but little change in ECV was seen over time. Baseline dyssynchrony was associated with worse outcome and deteriorated with time alongside LVEF decline. Conclusions: Results suggest that troponin I and cardiac MRI are sensitive translational tools in drug induced cardiotoxicity. However, troponin I is a relatively late marker, peaking after substantial myocardial damage, too late to halt or change reatment. The imaging suggests that fibrosis and inflammation cannot be detected within a year of chemotherapy but baseline ECV and strain analysis may have a role in risk stratification.

Knowledge about cardiac and inflammatory biomarkers in patients with stable coronary artery disease (CAD) is limited. To address this, we analyzed 3072 patients (36% female) with a median follow-up of 10 years in the Leipzig LIFE Heart Study with suspected CAD with coronary angiography. Selected biomarkers included troponin T (hsTNT), N-terminal pro B-type natriuretic peptide (NT-proBNP), copeptin, C-reactive protein (hsCRP), and interleukin-6 (IL-6). Patients were stratified by CAD severity: CAD0 (no sclerosis), CAD1 (non-obstructive, i.e., stenosis < 50%), and CAD2 (one stenosis 50%). Group comparison (GC) included GC1: CAD0 + 1 vs. CAD2; GC2: CAD0 vs. CAD1 + 2. CAD0, CAD1, and CAD2 were apparent in 1271, 631, and 1170 patients, respectively. Adjusted for classical risk factors, hs-cTnT, NT-proBNP, and IL-6 differed significantly in both GC and hsCRP only in GC2. After multivariate analysis, hs-cTnT, NT-proBNP, and IL-6 remained significant in GC1. In GC2, hs-cTnT (p < 0.001) and copeptin (p = 0.014) reached significance. Ten-year survival in groups CAD0, CAD1, and CAD2 was 88.3%, 77.3%, and 72.4%. Incorporation of hs-cTnT, NT-proBNP, copeptin, and IL-6 improved risk prediction (p < 0.001). The studied cardiac and inflammatory biomarkers enable fast and precise non-invasive identification of mortality risk in CAD patients, allowing the tailoring of primary and secondary CAD prevention.

<p>Introduction: Globally, more than 200 million patients undergo major non-cardiac surgery each year and more than 10 million patients will be exposed to postoperative myocardial ischemia, a condition strongly associated with 30-day mortality. The majority of these events go undetected without postoperative Troponin screening. Methods: We conducted a model-based cost-consequence analysis comparing a postoperative Troponin T screening vs. standard care in patients undergoing noncardiac surgery. In a first model, we evaluated the incremental number of detected perioperative myocardial infarctions and the incremental costs. A second model assessed the effect of the screening and consequent treatment on 1-year survival and the related cost. Model inputs based on the Vascular events In Non-cardiac Surgery patIents cOhort evaluatioN (VISION) Study, a large international cohort. We run probability sensitivity analyses with 5,000 iterations. We conducted extensive sensitivity analyses.</p> <p>Results: The cost to avoid missing an event amounted to CAD$ 5,184 for PMI and CAD$ 2,983 for isolated Troponin T. The cost-effectiveness of the postoperative Troponin screening was higher in patients’ subgroups at higher risk for PMI, e.g. patients undergoing urgent surgery. The incremental costs at 1 year of a postoperative PMI screening by 4 Troponin T measurements were CAD$ 169.20 per screened patient. The cost to prevent a death at 1 year amounted to CAD$ 96,314; however, there was relevant model uncertainty associated with the efficacy of the treatment in the 1-year model.</p> <p>Conclusion: Based on the estimated incremental cost per health gain, the implementation of a postoperative Troponin T screening after noncardiac surgery seems appealing, in particular in patients at high risk for perioperative myocardial infarction. However, decision-makers will have to consider it in terms of opportunity costs, i.e. in relation to the cost-effectiveness of other potential programs within the broader health care context.</p> / Master of Science (MSc)